Drug intelligence / Profile preview

RVL027

Development stage: Preclinical
Lead developer: Unravel Biosciences
Modality: Small Molecules

Overview

RVL027 is a small molecule drug candidate developed by Unravel Biosciences for the treatment of movement disorders, specifically X-linked dystonia-parkinsonism (XDP), dystonia, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). It is classified as an antiparkinsonian agent. The precise mechanism of action has not been defined or disclosed publicly. As of June 2024, it is considered a new molecular entity and has not received orphan drug designation from regulatory agencies[1][2].

Beyond the preview

Go deeper on RVL027.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RVL027.

Explore the full profile